Actively Recruiting
DFS and QOL After Modified Radical Mastectomy vs. Expanded Mckissock Surgery for EIC of the Breast
Led by Shengjing Hospital · Updated on 2022-02-08
200
Participants Needed
3
Research Sites
361 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Extensive intraductal carcinoma of the breast refers to a type of breast cancer in which ≥ 25% of ductal carcinoma in situ is present in invasive tumors and there is a scattered distribution of ductal carcinoma in situ (DCIS) in or around the invasive carcinoma. Compared with DCIS negative for extensive intraductal component, DCIS positive for extensive intraductal component is not sensitive to radiotherapy. Mckissock surgery was applied in breast-conserving surgery for breast cancer in 2016. Jianyi Li and the team members (Shengjing Hospital of China Medical University, Shenyang, China) applied this technique in breast-conserving surgery with preservation of the nipple-areola complex. This surgical technique is suitable for low-grade malignant tumors and has better prognosis than radical mastectomy. The purpose of this study is to investigate postoperative disease-free survival and quality of life after modified radical mastectomy versus expanded Mckissock surgery for extensive intraductal carcinoma of the breast. Results from this study will indicate the efficacy of expanded Mckissock surgery in the treatment of extensive intraducatal carcinoma of the breast.
CONDITIONS
Official Title
DFS and QOL After Modified Radical Mastectomy vs. Expanded Mckissock Surgery for EIC of the Breast
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with extensive intraductal carcinoma confirmed by hollow needle biopsy
- Lesion does not involve the nipple as shown by enhanced breast MRI
- Bra cup size B or higher
- Postmenopausal patients
- Provided written informed consent
You will not qualify if you...
- Positive cancer test twice at the edges of the nipple-areola complex
- Preoperative nipple bleeding
- Cancer in both breasts
- Inflammatory breast cancer
- Cancer spread to distant areas
- Other cancers or previous chest radiotherapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
General Hospital of Benxi Iron & Steel Industry Group of Liaoning Health Industry Group
Benxi, Liaoning, China, 117000
Actively Recruiting
2
Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute
Shengyang, Liaoning, China, 110042
Actively Recruiting
3
Shengjing Hospital of China Medical University
Shenyang, Liaoning, China, 110004
Actively Recruiting
Research Team
J
Jianyi Li
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here